Cdc25 phosphatases: structure, specificity, and mechanism - PubMed (original) (raw)

Review

. 2007 Mar 27;46(12):3595-604.

doi: 10.1021/bi700026j. Epub 2007 Mar 1.

Affiliations

• PMID: 17328562
• DOI: 10.1021/bi700026j

Review

Cdc25 phosphatases: structure, specificity, and mechanism

Johannes Rudolph. Biochemistry. 2007.

Abstract

Cdc25 phosphatases, as activators of the Cdk/cyclins, play critical roles in the regulation of the eukaryotic cell cycle. Because of their overexpression and correlation with poor prognosis in many diverse cancers, Cdc25 phosphatases are attractive targets for anticancer drug development. Over the past few years, much knowledge of the basic enzymology of the Cdc25 phosphatases that may aid in the development of specific inhibitors has been gained. We review herein the structure, specificity, and mechanism of the Cdc25 phosphatases with a special focus on the activity of Cdc25 phosphatases with native protein substrates.

PubMed Disclaimer

Similar articles

• Cdc25 phosphatases and cancer.
  Kristjánsdóttir K, Rudolph J. Kristjánsdóttir K, et al. Chem Biol. 2004 Aug;11(8):1043-51. doi: 10.1016/j.chembiol.2004.07.007. Chem Biol. 2004. PMID: 15324805 Review.
• Inhibitors of the CDC25 phosphatases.
  Prevost GP, Brezak MC, Goubin F, Mondesert O, Galcera MO, Quaranta M, Alby F, Lavergne O, Ducommun B. Prevost GP, et al. Prog Cell Cycle Res. 2003;5:225-34. Prog Cell Cycle Res. 2003. PMID: 14593717 Review.
• Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.
  Lavecchia A, Di Giovanni C, Novellino E. Lavecchia A, et al. Expert Opin Ther Pat. 2010 Mar;20(3):405-25. doi: 10.1517/13543771003623232. Expert Opin Ther Pat. 2010. PMID: 20166845 Review.
• CDC25 phosphatases in cancer cells: key players? Good targets?
  Boutros R, Lobjois V, Ducommun B. Boutros R, et al. Nat Rev Cancer. 2007 Jul;7(7):495-507. doi: 10.1038/nrc2169. Nat Rev Cancer. 2007. PMID: 17568790 Review.
• Inhibiting transient protein-protein interactions: lessons from the Cdc25 protein tyrosine phosphatases.
  Rudolph J. Rudolph J. Nat Rev Cancer. 2007 Mar;7(3):202-11. doi: 10.1038/nrc2087. Epub 2007 Feb 8. Nat Rev Cancer. 2007. PMID: 17287826 Review.

Cited by

• Voltage sensitive phosphatases: emerging kinship to protein tyrosine phosphatases from structure-function research.
  Hobiger K, Friedrich T. Hobiger K, et al. Front Pharmacol. 2015 Jan 10;6:20. doi: 10.3389/fphar.2015.00020. eCollection 2015. Front Pharmacol. 2015. PMID: 25713537 Free PMC article. Review.
• CDC25B partners with PP2A to induce AMPK activation and tumor suppression in triple negative breast cancer.
  Cairns J, Ly RC, Niu N, Kalari KR, Carlson EE, Wang L. Cairns J, et al. NAR Cancer. 2020 Dec;2(4):zcaa039. doi: 10.1093/narcan/zcaa039. Epub 2020 Dec 21. NAR Cancer. 2020. PMID: 33385163 Free PMC article.
• Exploiting synthetic lethal interactions for targeted cancer therapy.
  Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Reinhardt HC, et al. Cell Cycle. 2009 Oct 1;8(19):3112-9. doi: 10.4161/cc.8.19.9626. Cell Cycle. 2009. PMID: 19755856 Free PMC article. Review.
• An overview of stress response and hypometabolic strategies in Caenorhabditis elegans: conserved and contrasting signals with the mammalian system.
  Lant B, Storey KB. Lant B, et al. Int J Biol Sci. 2010 Jan 7;6(1):9-50. doi: 10.7150/ijbs.6.9. Int J Biol Sci. 2010. PMID: 20087441 Free PMC article. Review.
• Rhodanese-Fold Containing Proteins in Humans: Not Just Key Players in Sulfur Trafficking.
  Alsohaibani R, Claudel AL, Perchat-Varlet R, Boutserin S, Talfournier F, Boschi-Muller S, Selles B. Alsohaibani R, et al. Antioxidants (Basel). 2023 Mar 31;12(4):843. doi: 10.3390/antiox12040843. Antioxidants (Basel). 2023. PMID: 37107218 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal